Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here’s a rundown of the temperature-controlled supply chain solutions company’s report.CYRX is holding steady in today’s choppy market. See if it is worth your attention here.Q3 Highlights: Cryoport reported third-quarter revenue of $44.2 million, beating analyst estimates of $41.36 million, according to Benzinga Pro. The company reported a third-quarter loss of 18 cents per share, beating estimates for a ...

EQT has finished November higher only three times in the last 10 yearsWall Street is struggling amid AI overvaluation fears, as well as warnings from chief executives at Morgan Stanley (MS) and Goldman Sachs (GS) of an up to 20% equity market pullback in the next one to two years. Whether you lean bullish or bearish, it's good to take a look at our list of historical underperformers and outperformers for the month.EQT Corp (NYSE:EQT) takes the top spot on Schaeffer's Senior Quantitative Analyst Rocky White ...

MCLEAN, VA / ACCESS Newswire / November 4, 2025 / Gladstone Investment Corporation (Nasdaq: GAIN) (the "Company") today announced earnings for its second fiscal quarter ended September 30, 2025. Please read the Company's Quarterly Report on Form 10-Q, filed today with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov or the investors section of the Company's website at www.gladstoneinvestment.com. ...

Advanced Micro Devices forecast fourth-quarter revenue above market estimates on Tuesday, betting on the multibillion-dollar expansions of data center infrastructure to boost demand for its artificial... ...

Palantir's stock fell sharply on Tuesday despite upbeat earnings, while its CEO criticized short sellers. ...

Accessibility StatementSkip Navigation DALLAS, Nov. 4, 2025 /PRNewswire/ -- The Board of Directors of Comerica Incorporated (NYSE: CMA) declared a quarterly cash dividend for common stock of 71 cents ($0.71) per share. The dividend is payable Jan. 1, 2026, to shareholders of record at the close of business on Dec. 15, 2025. The Board also declared a cash dividend of $26.74 per share (equivalent to $0.6684 per depositary share) on the Series B Non-Cumulative Perpetual Preferred Stock of Comerica Incorporated ...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)---- $LTC #LTC--LTC Properties, Inc. (NYSE: LTC) ("LTC†or the "Company†), a real estate investment trust that primarily invests in seniors housing and health care properties, today announced operating results for the third quarter ended September 30, 2025. Recent Operating Highlights Closed approximately 85% of projected $460 million pipeline through November 4, more than $290 million of which was added to SHOP. SHOP portfolio at September 30, 2025 grew to nearly $ ...

Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire / November 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2025. ...

Supermicro (SMCI) stock dropped more than 8% before the bell on Wednesday as the AI server maker reported revenue and earnings for the first quarter of its 2026 fiscal year that fell below Wall Street's expectations. The company reported revenue of $5.02 billion for the first quarter, down from $5.94 billion during the year-ago period and less than the $6.09 billion expected by analysts, according to Bloomberg consensus estimates. Supermicro's adjusted earnings per share of $0.35 was also lower than the ...

Core Insights - Exact Sciences Corporation is a key player in the healthcare sector, focusing on cancer prevention and early detection with products like Cologuard and Oncotype DX [1] - The company reported strong third-quarter results, with earnings of 24 cents per share and quarterly sales of $850.7 million, exceeding expectations [3][6] - Robert W. Baird set a price target of $88 for EXAS, indicating a potential increase of about 22.11% from the current stock price [2][6] Financial Performance - The stock's current price is $70.94, reflecting a 5.91% rise or $3.96, with a market cap of $13.43 billion [2][5] - Exact Sciences raised its full-year 2025 sales guidance to $3.22 billion-$3.235 billion following the strong quarterly performance [3] - The trading volume for EXAS is 3,962,279 shares on the NASDAQ exchange, with the stock fluctuating between $67.97 and $72.81 on the reporting day [2][5] Strategic Focus - CEO Kevin Conroy emphasized the company's commitment to cancer prevention and early detection, highlighting the success of their patient-centric platform [4] - The momentum from successful products like Cologuard and Oncotype DX is driving growth and advancing new tests such as Cancerguard [4][6] - The company's innovative products and strong financial performance position it well for future growth [5][6]